GeneFerm Biotechnology Co., Ltd. (TPEX:1796)
Taiwan
· Delayed Price · Currency is TWD 40.00
-1.60 (-3.85%)
Mar 9, 2026, 1:30 PM CST
GeneFerm Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 677.1 | 521.16 | 793.77 | 633.96 | 522.33 | Upgrade
|
| Revenue Growth (YoY) | 29.92% | -34.34% | 25.21% | 21.37% | 41.82% | Upgrade
|
| Cost of Revenue | 486.3 | 424.42 | 507.42 | 411.8 | 329.68 | Upgrade
|
| Gross Profit | 190.8 | 96.75 | 286.35 | 222.16 | 192.65 | Upgrade
|
| Selling, General & Admin | 111.22 | 102.93 | 104.88 | 96.71 | 88.82 | Upgrade
|
| Research & Development | 33.54 | 29.31 | 28.33 | 24.18 | 23.56 | Upgrade
|
| Operating Expenses | 144.72 | 131.15 | 132.79 | 120.17 | 113.82 | Upgrade
|
| Operating Income | 46.08 | -34.41 | 153.57 | 101.99 | 78.84 | Upgrade
|
| Interest Expense | -6.22 | -4.44 | -4.17 | -3.82 | -7.32 | Upgrade
|
| Interest & Investment Income | 1.82 | 1.54 | 0.92 | 0.33 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 4.8 | 0.84 | 9.66 | -2.67 | Upgrade
|
| Other Non Operating Income (Expenses) | -6.98 | 5.03 | 2.27 | 2.6 | 1.51 | Upgrade
|
| EBT Excluding Unusual Items | 34.7 | -27.49 | 153.42 | 110.76 | 70.57 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.43 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.02 | 0.01 | -0.11 | 0.04 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.21 | Upgrade
|
| Pretax Income | 34.7 | -27.47 | 153.43 | 110.21 | 70.4 | Upgrade
|
| Income Tax Expense | 5.83 | -4.94 | 28.81 | 16.76 | 12.98 | Upgrade
|
| Net Income | 28.86 | -22.53 | 124.62 | 93.45 | 57.41 | Upgrade
|
| Net Income to Common | 28.86 | -22.53 | 124.62 | 93.45 | 57.41 | Upgrade
|
| Net Income Growth | - | - | 33.35% | 62.78% | 1167.67% | Upgrade
|
| Shares Outstanding (Basic) | 41 | 41 | 41 | 41 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 41 | 41 | 42 | 43 | 46 | Upgrade
|
| Shares Change (YoY) | -0.55% | -0.36% | -2.26% | -8.00% | 65.83% | Upgrade
|
| EPS (Basic) | 0.70 | -0.54 | 3.01 | 2.26 | 1.45 | Upgrade
|
| EPS (Diluted) | 0.70 | -0.54 | 2.99 | 2.20 | 1.32 | Upgrade
|
| EPS Growth | - | - | 35.63% | 66.87% | 725.71% | Upgrade
|
| Free Cash Flow | 75.89 | -14.31 | 120.37 | -155.74 | -32.65 | Upgrade
|
| Free Cash Flow Per Share | 1.84 | -0.34 | 2.89 | -3.66 | -0.70 | Upgrade
|
| Dividend Per Share | - | - | 2.000 | 1.500 | 1.000 | Upgrade
|
| Dividend Growth | - | - | 33.33% | 50.00% | 1103.93% | Upgrade
|
| Gross Margin | 28.18% | 18.56% | 36.08% | 35.04% | 36.88% | Upgrade
|
| Operating Margin | 6.80% | -6.60% | 19.35% | 16.09% | 15.09% | Upgrade
|
| Profit Margin | 4.26% | -4.32% | 15.70% | 14.74% | 10.99% | Upgrade
|
| Free Cash Flow Margin | 11.21% | -2.74% | 15.17% | -24.57% | -6.25% | Upgrade
|
| EBITDA | 120.56 | 37.89 | 219.41 | 145.16 | 117.76 | Upgrade
|
| EBITDA Margin | 17.80% | 7.27% | 27.64% | 22.90% | 22.55% | Upgrade
|
| D&A For EBITDA | 74.48 | 72.3 | 65.84 | 43.16 | 38.92 | Upgrade
|
| EBIT | 46.08 | -34.41 | 153.57 | 101.99 | 78.84 | Upgrade
|
| EBIT Margin | 6.80% | -6.60% | 19.35% | 16.09% | 15.09% | Upgrade
|
| Effective Tax Rate | 16.81% | - | 18.78% | 15.21% | 18.44% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.